up with MSLTs every 6-12 months. Thus the purpose of this study was to compare the use of the MSLT and ESS in evaluating the efficacy of modafinil in patients with narcolepsy.
METHODS
We included a total of 10 consecutive patients with narcolepsy-with-cataplexy treated at our sleep center from January 2003 to December 2007 (Tables 1 and 2 ). Narcolepsy was diagnosed according to the criteria established by the International Classification of Sleep Disorders, Second Edition [2] , which included the following: EDS occurring almost daily for at least 3 months; a definite history of cataplexy; objective confirmation by nocturnal polysomnography (PSG) followed by a next-day MSLT; mean sleep latency on MSLT is ≤ 8 minutes, with two or more sleep-onset rapid eye movement (REM) periods present in the MSLT after sufficient nocturnal sleep (minimum 6 hours) during the preceding nocturnal PSG; and hypersomnia is not better explained by another sleep disorder, neurological disorder, mental disorder, medication use, or substance use.
A comprehensive questionnaire covering lifetime sleep-wake, medical and psychiatric history, and a review of sleeping and medical symptoms was completed for these 10 patients, which included the Chinese version of the ESS [3] . Neurological examinations and psychiatric interviews were also conducted. Brain magnetic resonance imaging and biochemistry screening (fasting blood sugar, liver function, renal function and thyroid function) were also performed. Overnight, hospital-based, PSG monitoring, using standard recording and scoring methods [4] , was performed for these 10 patients 8 weeks after discontinuing any prior medications. The PSG monitoring included eye movements (electrooculogram); routine electroencephalographic montage; submental and anterior tibialis electromyograms; oral-nasal airflow, chest and abdomen respiratory effort; electrocardiogram; and continuous time-synchronized audiovisual recording. MSLT was performed every 2 hours, starting after a spontaneous morning awakening from the overnight PSG study. Sleep latency was defined as the time to the first epoch of stage 2-4 non-REM or REM sleep, or the first three continuous epochs of stage 1 sleep [4] .
After the patients were diagnosed as having narcolepsy with cataplexy, modafinil therapy was initiated at a standard dose of 200 mg taken every morning. After 6-12 months of ongoing therapy, all 10 patients underwent MSLT (after at least 6 hours of nocturnal sleep) and ESS. 
RESULTS
Brain magnetic resonance imaging and biochemistry data were unremarkable in these 10 patients. The PSG results and baseline (i.e. pretreatment) MSLT and ESS scores are shown in Table 3 . The mean age at narcolepsy onset was 11.8 ± 3.3 years, and eight (80%) patients were male. PSG also identified one patient (10%) with mild obstructive sleep apnea (Respiratory Disturbance Index, 16.8/hr, with minimal oxygen desaturation nadirs of 90-95%), which was managed with weight loss therapy rather than with continuous positive airway pressure therapy. Mean body mass index was 26.9 ± 6.0 kg/m 2 , which was in the overweight range. Four (40%) patients showed modest periodic limb movement during sleep, as shown in Table 3 , without clinical correlates. No patient had restless legs syndrome. The mean ESS score was 20.0 ± 1.6, and the mean MSLT sleep latency was 1.7 ± 0.8 minutes.
Modafinil was taken once daily in the morning by all 10 patients and was very well tolerated. Treatmentrelated adverse experiences were rare and were mostly mild, including palpitations after intense exercise. No patient expressed a need to take a dose higher than the initial dose of 200 mg. After 6-12 months of treatment with 200 mg/day modafinil, all 10 patients underwent MSLT and ESS. At this time, the mean MSLT sleep latency was 2.2 ± 1.0 minutes and the mean ESS score was 13.8 ± 3.3. Only one patient received separate therapy for cataplexy, consisting of low-dose 25 mg/day imipramine. Many of the patients reported a substantial improvement in cataplexy with modafinil therapy (Table 3) .
We performed statistical analysis using paired t tests for within-subject comparisons and the results are expressed as mean ± standard deviation (Tables 2  and 4 ). As shown in Table 4 , we found that there were significant pretreatment versus post-treatment differences in the mean MSLT sleep latency and ESS scores in these 10 patients. However, the MSLT sleep latency scores remained in the pathologically sleepy range. Therefore, this statistically significant difference does not reflect a clinically significant change. The difference in ESS score after modafinil therapy was more significant compared with the difference in MSLT score. The changes in ESS score indicate clinically significant effects of modafinil. Treatment was not associated with any changes in body mass index, as shown in Table 4 . 
DISCUSSION
In this first report on modafinil therapy for narcolepsy in Taiwan, our MSLT data are consistent with the previously published results of multicenter studies using different research designs. There was variable or suboptimal improvement in the MSLT latencies with traditional stimulants used to treat narcolepsy, e.g. methylphenidate and amphetamine [5, 6] . Furthermore, the authors of a controlled PSG study comprising 25 patients with narcolepsy being treated with traditional stimulants and 25 controls, reported that "despite taking their usual medications, narcoleptic subjects averaged 44 minutes of daytime sleep compared with 4.8 minutes for controls… These findings indicate that daytime sleep episodes were common in narcoleptic patients who considered their treatment satisfactory" [7] . In Caucasian populations, "results from several multicenter studies indicated that modafinil had a significant impact on the objective measures of sleepiness; however, the improvement noted on MSLT was never normalized. This suggests that narcolepsy is a complex disorder in which the mechanisms underlying daytime sleepiness are not yet well understood" [8] . Our study is the first to report similar MSLT data in an Asian population (in Taiwan) of narcoleptic-cataplectic patients, and to support the use of the ESS for monitoring the longitudinal efficacy of modafinil therapy in Taiwan. The ESS is a self-administered questionnaire comprising eight items, and is described in more detail elsewhere [9] . It asks the subject to rate on a four-point scale his/her chances of dozing in each of eight different situations that are often encountered in daily life. The situations were chosen owing to their potential ability to induce dozing/sleepiness. The scores for each item of the ESS provide a measure for one situation that could induce sleep. The MSLT is a daytime test that measures how quickly the subject falls asleep objectively, during five structured nap opportunities separated by 1.5-2-hour intervals [10] . During each nap opportunity, the patient is asked to go to bed in a quiet, darkened bedroom for 20 minutes, while being monitored by standard PSG equipment. For the MSLT data to be valid, the patient needs to sleep for a minimum of 6 hours during the preceding nocturnal PSG. The sleep latency during each nap opportunity is documented objectively. If the patient does not sleep then, by definition, the sleep latency for that nap is scored as 20 minutes. The mean sleep latency is determined from the sleep latencies identified during the four (or 5-6) structured nap opportunities.
In a study by Sangal et al [11] of 522 drug-free patients with narcolepsy, the mean MSLT was 2.8 ± 3.8 minutes, and the mean ESS score was 17.7 ± 3.8. This is similar to our findings where 10 drug-free patients with narcolepsy had a mean ESS was 20.00 ± 1.63 and a mean MSLT of 1.72 ± 0.80 minutes. After our patients were treated with 200 mg/day modafinil for 6-12 months, the mean MSLT increased to 2.16 ± 0.96 minutes and the mean ESS score decreased to 13.80 ± 3.26. The mean ESS score of 13.8 approximated the normative score of 12 for the ESS. In contrast, the change in MSLT sleep latency from 1.72 to 2.16 minutes, although statistically significant, was not clinically significant, remaining in the pathologic range. In contrast, the change in ESS score from 20.0 to 13.8 appears to be clinically significant and matches the patients' reports during follow-up visits on improvements in their EDS with modafinil therapy. This marked improvement was also reflected by the finding that none of the patients requested an increase in modafinil dose.
Modafinil is a pharmacologically and clinically promising compound for the treatment of pathologic daytime sleepiness found in narcolepsy. Although the MSLT is the "gold standard" for objectively establishing the presence of daytime sleepiness in narcolepsy, it has poor sensitivity for measuring improvements in The ESS has a major advantage over the MSLT in terms of its very low cost and ease of administration. Furthermore, the ESS appears to be quite sensitive and clinically useful for evaluating the efficacy of modafinil for narcolepsy.
Some caution is needed when interpreting our findings. First, a placebo effect in the ESS findings may have been present in this uncontrolled study. The lack of a control group could at least partly explain the differences in ESS and MSLT scores, since a placebo effect is a subjective effect, and the ESS is a subjective test. On this basis, the MSLT may be a more accurate reflection of daytime sleepiness. Second, a higher dose of modafinil may have affected the results differently although, as already stated, no patient requested an increase in modafinil dose. Third, the MSLT and ESS appear to assess different aspects of narcoleptic sleepiness. The ESS may reflect average daily sleep propensities in the patients' natural environment, whereas the MSLT may reflect one situation-specific sleep propensity, i.e. structured naps in the "artificial" environment of the sleep laboratory. These comments about the ESS and MSLT are relevant not only to our study, but also to the studies cited in this discussion regarding traditional stimulant therapy for narcolepsy.
